| Company
| Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
GlaxoSmithKline plc (ADR)
| NYSE
|
GSK
|
52.94
|
|
+0.29
(0.55%)
| 129.96B
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
GlaxoSmithKline plc
| LON
|
GSK
|
1,764.50
|
|
-8.50
(-0.48%)
| 85.47B
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
IPG Investment Partners Group AG
| ETR
|
GSK
|
0.0000
|
|
|
|
|
|
IPG Investment Partners Group AG, formerly known as IPG Investment Partners
Group Wertpapierhandelsbank AG, is a Germany-based investment bank for ...
| |
| |
|
|
GlaxoSmithKline PLC
| FRA
|
GS7
|
20.00
|
|
-0.67
(-3.24%)
|
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
Cyclacel Pharmaceuticals Inc
| NASDAQ
|
CYCC
|
2.99
|
|
-0.08
(-2.61%)
| 25.22M
|
|
|
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the
immune system to treat cancer and other serious illnesses.
| |
| |
|
|
Cytokinetics, Inc.
| NASDAQ
|
CYTK
|
1.13
|
|
-0.02
(-1.74%)
| 165.50M
|
|
|
Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused
on the discovery and development of small molecule therapeutics that ...
| |
| |
|
|
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
| NASDAQ
|
CYCCP
|
7.66
|
|
0.00
(0.00%)
| 3.22M
|
|
|
|
|
|
CYTOKINETICS INC. DL-,001
| FRA
|
KK3
|
0.884
|
|
0.000
(0.00%)
|
|
|
|
|
|
|
CYCLACEL PHARM. DL-,001
| FRA
|
UXI2
|
2.32
|
|
0.00
(0.00%)
|
|
|
|
|
|
